Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 14, 2024 07:00 ET | Source: Pluri Inc.

Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing

HAIFA, Israel, March 14, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions, today...
March 11, 2024 07:00 ET | Source: Pluri Inc.

Pluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation

HAIFA, Israel, March 11, 2024 (GLOBE NEWSWIRE) -- In a strategic move that underscores its innovative edge in the agtech sector, Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company") today...
March 06, 2024 07:00 ET | Source: Pluri Inc.

Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

HAIFA, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote...
February 28, 2024 07:00 ET | Source: Pluri Inc.

Pluri’s Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals

Growing pipeline of industry-specific new potential products, services, collaborations and partnerships through PluriAgtech, PluriCDMO, PluriHealth, and PluriFoodRecent achievements include: new...
January 23, 2024 02:00 ET | Source: Pluri Inc.

Step into the Future: Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis

Pluri to leverage its proprietary 3D technology platform to develop cell-based products for the coffee industry under its new business vertical PluriAgtechThe rapidly growing $130 billion coffee...
January 08, 2024 07:00 ET | Source: Pluri Inc.

Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization

Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization
December 21, 2023 07:00 ET | Source: Pluri Inc.

Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction

Agreement signed following positive pre-clinical data demonstrating a one-time treatment with PLX-PAD significantly increased neurogenesis, offering immediate, long-term therapeutic effect in treating...
August 16, 2023 07:00 ET | Source: Pluri Inc.

Pluri’s PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in a Phase I Study: Results Published in Nature Bone Marrow Transplantation

Results support the development of PLX-R18 for hematologic acute radiation syndrome (H-ARS), currently under a $4.2 million contract with the U.S. National Institutes of HealthPLX-R18 has the...
July 13, 2023 02:00 ET | Source: Pluri Inc.

Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors

HAIFA, Israel, July 13, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote...
July 11, 2023 02:00 ET | Source: Pluri Inc.

U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluri’s PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Syndrome

Pluri's cell therapy is designed to be the first in class, effective treatment for ionizing radiation poisoning in the event of a large-scale nuclear incident.The work specified by the contract is...